» Articles » PMID: 23143028

Percutaneous Recanalization for Budd-Chiari Syndrome: an 11-year Retrospective Study on Patency and Survival in 177 Chinese Patients from a Single Center

Overview
Journal Radiology
Specialty Radiology
Date 2012 Nov 13
PMID 23143028
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the long-term outcomes of percutaneous recanalization and determine the predictors of patency and survival in a large case series of Chinese patients with Budd-Chiari syndrome (BCS).

Materials And Methods: This retrospective study was approved by the institutional ethics committee. Informed consent for the procedure was obtained from all patients. Between July 1999 and August 2010, 177 consecutive Chinese patients with primary BCS were treated with percutaneous recanalization and followed up until death or their last clinical evaluation. Recanalization therapeutic strategy and complications were recorded. Cumulative patency and survival rates were assessed with Kaplan-Meier curves. Independent predictors of patency and survival were calculated with the Cox regression model.

Results: Percutaneous recanalization was technically successful in 168 of the 177 patients (95%). Fifty-one of the 168 patients (30%) were treated with percutaneous transluminal angioplasty (PTA) alone and 117 (70%) were treated with a combination of PTA and stent placement. Procedure-related complications occurred in seven of the 168 patients (4%). The cumulative 1-, 5-, and 10-year primary patency rates were 95%, 77%, and 58%, respectively. Independent predictors of reocclusion included increased white blood cell count and use of PTA alone. The cumulative 1-, 5-, and 10-year secondary patency rates were 97%, 90%, and 86%, respectively. Twenty-two patients died during a median follow-up of 30 months (range, 0.25-137 months). The cumulative 1-, 5-, and 10-year survival rates were 96%, 83%, and 73%, respectively. Independent predictors of survival included variceal bleeding, increased alkaline phosphatase and blood urea nitrogen levels, and reocclusion.

Conclusion: Percutaneous recanalization could achieve excellent long-term patency and survival in most Chinese patients with BCS. PTA combined with stent placement should be recommended to decrease the frequency of reocclusion and its associated mortality.

Citing Articles

Interventions in Budd-Chiari syndrome: an updated review.

Patel R, Chandel K, Tripathy T, Behera S, Panigrahi M, Nayak H Abdom Radiol (NY). 2024; 50(3):1307-1319.

PMID: 39325211 DOI: 10.1007/s00261-024-04558-4.


Percutaneous hepatic vein recanalization in pediatric Budd-Chiari syndrome - 10 years' experience from a tertiary center.

Sastry U, Doddaiah M, Arunakumar P, Marimuthu V, Kasturi S, Srinivas B Ann Pediatr Cardiol. 2023; 16(3):168-174.

PMID: 37876952 PMC: 10593285. DOI: 10.4103/apc.apc_160_22.


Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis.

Lv L, Xu H, Li S, Xu P BMC Gastroenterol. 2023; 23(1):340.

PMID: 37784064 PMC: 10546748. DOI: 10.1186/s12876-023-02969-z.


Interventional Treatment of Budd-Chiari Syndrome.

Rossle M Diagnostics (Basel). 2023; 13(8).

PMID: 37189559 PMC: 10137827. DOI: 10.3390/diagnostics13081458.


Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review.

Mukhiya G, Jiao D, Han X, Zhou X, Pokhrel G J Clin Imaging Sci. 2023; 13:5.

PMID: 36751561 PMC: 9899460. DOI: 10.25259/JCIS_130_2022.